Novo Nordisk shares surge on results of new obesity drug trial
2 hours ago · Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share price on Friday.
Novo Nordisk successfully completes phase 1b/2a trial with …
3 days ago · Bagsværd, Denmark, 24 January 2025 – Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor agonist intended for ...
Novo Nordisk shares pop on early-stage weight loss drug trial …
3 days ago · Shares of Novo Nordisk jumped Friday after the Danish pharmaceutical giant reported positive early-stage results for its once weekly amycretin obesity drug. The trial showed average weight ...
Novo Rises as Experimental Shot Shows 22% Weight Loss
2 days ago · Novo Nordisk A/S rose the most since August 2023 after its experimental shot delivered as much as 22% weight loss in an early-stage trial, boosting investors’ hopes for the drugmaker’s pipeline.
Latest news - Novo Nordisk
Jan 8, 2025 · Novo Nordisk successfully completes phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity
Compounded semaglutide associated with at least 10 deaths, Novo Nordisk …
Nov 6, 2024 · Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have been associated with at least 100 hospitalizations and 10 deaths, the chief...
Company announcements & press releases - Novo Nordisk
Novo Nordisk A/S: Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence
News Details - novonordisk.com
Oct 21, 2024 · Novo Nordisk A/S: Oral semaglutide demonstrates a 14% reduction in risk of major adverse cardiovascular events in adults with type 2 diabetes in the SOUL trial Bagsværd, Denmark, 21 October 2024 — Novo Nordisk today announced the headline results from the SOUL cardiovascular outcomes trial.
Novo Nordisk U.S. News & Media Hub | Novo Nordisk U.S.
View financial meetings and events, strategic aspirations for 2025 and contact information for investor relations. A place to find different points of view from inside Novo Nordisk and the communities we serve. Welcome to Novo Nordisk's U.S. news and media hub.
Novo Nordisk shares jump on fresh trial results - Financial Times
2 days ago · Shares in Novo Nordisk, one of Europe’s most valuable companies, jumped 8 per cent on Friday after the pharmaceutical group announced positive results from the latest trial of weight-loss ...